More News! 8 Apr 2017 These Scientists are Turning the Human Brain into Art Neuroimaging artist duo DiMa takes the popular saying “beauty is inside” to another level by transforming complex visualizations of the brain into art. Diana Roettger and Matthew Rowe, who work together under the artistic name DiMa, are two imaging scientists that create art directly from scientific research. Originally from Germany and the UK, respectively, both hold […] April 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 7 Apr 2017 This Biotech Mining Probiotics to Treat the Skin has IPO’d in London SkinBioTherapeutics has raised £4,5M in its IPO on the London Stock Exchange to advance its probiotic technology for skin health applications. SkinBioTherapeutics, a spin-out from the University of Manchester, made its debut this week in AIM, the London Stock Exchange’s market for smaller growing companies. The £4,5M (€5.25M) raised will be used to continue the development […] April 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2017 This New Biotech counts with the Largest Antibiotic Resistance Database Curetis has launched Ares Genetics, a company that will use the biggest antibiotic resistance genetic database to advance the diagnose of infections. Ares Genetics, the new subsidiary of Curetis, will investigate the genetic foundation of antibiotic resistance to develop new approaches for the rapid diagnose of specific resistance in patients with infections, as well as tools to […] April 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2017 Massive €800M Acquisition of Belgian Biotech treating Menopause Astellas Pharma is acquiring Ogeda, getting hold of its promising Phase II candidate to treat menopause without hormonal therapy. After acquiring Ganymed Pharmaceuticals last October for a record €1.3B in German biotech, the Japanese Astellas Pharma is making a second massive acquisition in Europe. Its new addition is Ogeda, a Belgian biotech targeting GPCRs to treat gynecological […] April 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2017 New Results Show GM Mosquitoes Keep Dengue and Zika at Bay in Brazil In its second year, Oxitec has reduced the mosquito population in a Brazilian neighborhood by 81%, demonstrating the long-term potential of GM insects. Oxitec is a spin-out from the University of Oxford that fights infectious disease with genetically-engineered mosquitoes that produce inviable offspring. The company has already made field trials in the Cayman Islands, Panama, Brazil, […] April 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 1 Apr 2017 Will we Rely on Biomining to Build the Tech Devices of the Future? The Danish artist Jacob Remin explores how biotech might be essential if we want to keep building smartphones and laptops. Computers, tablets, phones, television screens… we take our electronic devices for granted. However, the rapidly increasing demand might not be possible to meet because of rare earth elements, a series of rare metals that are […] April 1, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2017 Swiss Antibodies Recruited by the Developer of BMS’ Cancer Blockbuster Ono Pharmaceutical is offering the Swiss Numab €241M (CHF 258M) for the development of a multi-specific antibody for immuno-oncology applications. Numab, one of the hottest biotechs in Zurich, has developed a unique technology to generate stable antibody fragments (not an easy feat!) and use them as building blocks for multi-specific antibodies that can target up […] March 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2017 Novartis puts the Development of two Anti-Aging Drugs in American Hands PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping the decline of the immune system associated with age. Novartis is building up the portfolio of PureTech, a Boston-based healthcare company listed on the London stock market. Originally an investment firm, it now has put together a drug pipeline from […] March 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 21 Mar 2017 Better than Quantum Computing: The EU Launches a Biocomputer Project The EU Horizon 2020 has launched Bio4Comp, a five-year €6.1M project to build more powerful and safer biocomputers that could outperform quantum computing. The Bio4Comp project has the ambitious goal of building a computer with greater processing speed and lower energy consumption than any of the most advanced computers existing today. Ultimately, this could translate into […] March 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Mar 2017 Wellcome Image Awards: These are the Best Biology Images of the Year The UK’s Wellcome trust has selected 22 pictures and images that capture the wonders of the life sciences. They’re now on exhibition in the UK and Ireland. The Wellcome Image Awards celebrates this year 20 years of bringing us the best biology images around the world. The awards are destined to visual masterpieces that communicate key aspects […] March 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2017 Can this British Biotech Overcome Failure buying drugs from AstraZeneca? After the big disaster with its cat allergy vaccine, Circassia closes a €214M deal to acquire rights from two AstraZeneca products for pulmonary disease. Circassia could not beat the placebo in a Phase III trial for cat allergy last year, which immediately drove its stock down by 65% and led to the halt of clinical […] March 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 16 Mar 2017 “In the Coming Decade, Off-the-Shelf Cell Therapy will Become a Reality” David Sourdive, co-founder of Cellectis, discusses his pioneering work developing off-the-shelf CAR-T for cancer and the future directions of cell therapy. Last week I had the opportunity to attend the World ADOPT Summit and hear from some of the world leaders in cell therapy. There I met David Sourdive, co-founder and EVP Technical Operations at Cellectis, […] March 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email